ADLT Final Rule Creates Tough Questions for Labs

Variety of circumstances will affect how labs that offer ADLTs react to the PAMA Final Rule

IT’S GOING TO BE A DIFFERENT AND TOUGHER WORLD for laboratory companies that market proprietary molecular and genetic tests. That’s the opinion of experts who have studied the final rule governing Advanced Diagnostic Laboratory Tests (ADLTs) that the federal Centers for Medicare & Medicaid Services issued in June. The final rule implements Section 216 of …

ADLT Final Rule Creates Tough Questions for Labs Read More »

To access this post, you must purchase The Dark Report.



You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.